{"id":"https://openalex.org/W2947833147","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","title":"High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).","display_name":"High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947833147","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","mag":"2947833147"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.10024","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043729995","display_name":"Brian H. Kushner","orcid":"https://orcid.org/0000-0002-8916-0697","observed_orcids":["https://orcid.org/0000-0002-8916-0697"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian H. Kushner","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105830310","display_name":"Shakeel I. Modak","orcid":"https://orcid.org/0000-0002-7280-1726","observed_orcids":["https://orcid.org/0000-0002-7280-1726"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shakeel Modak","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016432846","display_name":"Ellen M. Basu","orcid":"https://orcid.org/0000-0002-4555-220X","observed_orcids":["https://orcid.org/0000-0002-4555-220X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ellen M. Basu","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026950879","display_name":"Stephen S. Roberts","orcid":"https://orcid.org/0000-0001-8258-756X","observed_orcids":["https://orcid.org/0000-0001-8258-756X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen S. Roberts","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034081882","display_name":"Nai\u2010Kong V. Cheung","orcid":"https://orcid.org/0000-0001-6323-5171","observed_orcids":["https://orcid.org/0000-0001-6323-5171"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nai-Kong V. Cheung","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1334819555"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"10024","last_page":"10024"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/high-risk-neuroblastoma","display_name":"high-risk neuroblastoma","score":0.8920000195503235},{"id":"https://openalex.org/keywords/naxitamab","display_name":"naxitamab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/gm-csf","display_name":"GM-CSF","score":0.9570000171661377},{"id":"https://openalex.org/keywords/gd2-antibody","display_name":"GD2 antibody","score":0.6079999804496765},{"id":"https://openalex.org/keywords/bone-marrow-metastasis","display_name":"bone marrow metastasis","score":0.8309999704360962},{"id":"https://openalex.org/keywords/chemoresistance","display_name":"chemoresistance","score":0.7099999785423279},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8019999861717224},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7739999890327454},{"id":"https://openalex.org/keywords/mibg-therapy","display_name":"MIBG therapy","score":0.4480000138282776},{"id":"https://openalex.org/keywords/pediatric-cancer-immunotherapy","display_name":"pediatric cancer immunotherapy","score":0.5450000166893005},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5049999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8982735872268677},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5524194240570068},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.5435556769371033},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5347522497177124},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.5118443369865417},{"id":"https://openalex.org/C57742111","wikidata":"https://www.wikidata.org/wiki/Q7168","display_name":"Histology","level":2,"score":0.47597187757492065},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41911688446998596},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.38150712847709656},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34653568267822266},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3371506929397583},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3271980881690979},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.32262060046195984},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16227641701698303},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.10024","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.10024","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.800000011920929,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379280638","https://openalex.org/W3173034345","https://openalex.org/W7119824663","https://openalex.org/W4408303412","https://openalex.org/W4416723144","https://openalex.org/W3028893532","https://openalex.org/W7214014817","https://openalex.org/W7212390850","https://openalex.org/W4389480748","https://openalex.org/W3203496479"],"abstract_inverted_index":{"10024":[0],"Background:":[1],"Cure":[2],"of":[3,36,108,132,273],"HR-NB":[4,66],"often":[5],"requires":[6],"ablating":[7],"BM":[8,18,139],"metastases":[9],"that":[10],"are":[11],"chemoresistant":[12,70,266],"and":[13,42,54,98,125,149,177,187,198],"survive":[14],"131I-metaiodobenzylguanidine":[15],"(MIBG)":[16],"therapy.":[17],"is":[19,263,276],"ideal":[20],"for":[21,82],"immunotherapy":[22],"with":[23,58,68,115,243],"anti-GD2":[24],"antibodies":[25],"including":[26,240],"naxitamab":[27,91,274],"(humanized-3F8;":[28],"granted":[29],"FDA\u2019s":[30],"breakthrough":[31],"designation":[32],"in":[33,50,72,105,120,134,144,196,201,211,218,227,248,268,278],"2018)":[34],"because":[35],"excellent":[37],"accessibility":[38],"to":[39,84,112],"antibody,":[40],"complement,":[41],"effector":[43],"cells.":[44],"GM-CSF":[45,100],"exerts":[46],"a":[47,279],"dose-response":[48],"effect":[49],"antibody-dependent":[51],"cellular":[52],"cytotoxicity":[53],"significantly":[55],"improves":[56],"outcome":[57],"murine-3F8":[59],"(":[60,257],"JCO":[61],"2012;30:426).":[62],"Methods:":[63],"We":[64],"evaluated":[65],"patients":[67,168,206,214,231,250],"histologically-evident":[69],"disease":[71],"BM,":[73,269],"but":[74,156],"no":[75],"soft":[76],"tissue":[77],"or":[78],"prior":[79],"progressive":[80],"disease,":[81],"response":[83,209],"naxitamab+GM-CSF":[85],"on":[86],"protocol":[87],"(NCT01757626).":[88],"Cycles":[89,153],"comprised":[90],"infused":[92],"intravenously":[93],"(30":[94],"minutes)":[95],"x3":[96],"(Mon-Wed-Fri)":[97],"subcutaneously-administered":[99],"starting":[101],"5":[102,184],"days":[103],"pre-naxitamab":[104],"priming":[106],"doses":[107],"250\u00b5g/m2/day,":[109],"then":[110],"stepped-up":[111],"500\u00b5g/m2/day":[113],"beginning":[114],"antibody.":[116],"Naxitamab":[117],"was":[118,140],"dose-escalated":[119],"the":[121,135,223],"phase":[122,136,185,189],"I":[123,186],"portion":[124],"9mg/kg/cycle":[126],"(~270mg/m2/cycle,":[127],"i.e.,":[128],">":[129],"2.5x":[130],"dosage":[131],"ch14.18)":[133],"I/II":[137,190],"expansion.":[138],"assessed":[141],"post-cycle":[142,251],"2":[143,249],"aspirates+biopsies":[145],"from":[146,238],"bilateral":[147],"posterior":[148],"anterior":[150],"iliac":[151],"crests.":[152],"were":[154,157,172,183,254],"monthly":[155],"deferred":[158],"if":[159],"human":[160],"anti-human":[161],"antibody":[162],"(HAHA)":[163],"developed.":[164],"Results:":[165],"The":[166],"19":[167],"enrolled":[169],"through":[170],"5/2018":[171],"5m-to-19m":[173],"(median":[174,180,235],"7.5m)":[175],"post-diagnosis":[176],"age":[178],"2y10m-to-10y1m":[179],"5y2m).":[181],"Included":[182],"14":[188],"patients.":[191,203],"Histology":[192],"showed":[193,225],"primitive":[194],"NB":[195,217,267],"12":[197,228],"ganglioneuromatous":[199],"cells":[200],"7":[202],"All":[204],"(100%)":[205],"achieved":[207],"complete":[208],"(CR)":[210],"BM.":[212],"16":[213],"also":[215],"had":[216],"bone/BM":[219],"by":[220],"123I-MIBG":[221],"scan;":[222],"latter":[224],"CR":[226],"(75%).":[229],"11":[230],"remained":[232],"progression-free":[233],"20+-to-54+":[234],"27+)":[236],"months":[237],"enrollment,":[239],"10":[241],"treated":[242],"anti-NB":[244],"vaccine.":[245],"HAHA":[246],"developed":[247],"2.":[252],"Toxicities":[253],"as":[255],"expected":[256],"JAMA":[258],"Oncol":[259],"2018;4:1729).":[260],"Conclusions:":[261],"Naxitamab+GM-CSF":[262],"effective":[264],"against":[265],"supporting":[270],"further":[271],"development":[272],"which":[275],"proceeding":[277],"pivotal":[280],"international":[281],"trial":[282,285],"(NCT02502786).":[283],"Clinical":[284],"information:":[286],"NCT01757626.":[287]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-06-07T00:00:00"}